The role of delamanid in the treatment of drug-resistant tuberculosis

Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK Abstract: Tuberculosis (TB) remains a significant cau...

Full description

Saved in:
Bibliographic Details
Main Authors: Lewis JM (Author), Sloan DJ (Author)
Format: Book
Published: Dove Medical Press, 2015-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ee5bb99e076149ffbb06fb1ac67d79fc
042 |a dc 
100 1 0 |a Lewis JM  |e author 
700 1 0 |a Sloan DJ  |e author 
245 0 0 |a The role of delamanid in the treatment of drug-resistant tuberculosis 
260 |b Dove Medical Press,   |c 2015-05-01T00:00:00Z. 
500 |a 1178-203X 
520 |a Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK Abstract: Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management. Keywords: delamanid, OPC-67683, tuberculosis, drug resistance, MDR-TB  
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Therapeutics and Clinical Risk Management, Vol 2015, Iss default, Pp 779-791 (2015) 
787 0 |n http://www.dovepress.com/the-role-of-delamanid-in-the-treatment-of-drug-resistant-tuberculosis-peer-reviewed-article-TCRM 
787 0 |n https://doaj.org/toc/1178-203X 
856 4 1 |u https://doaj.org/article/ee5bb99e076149ffbb06fb1ac67d79fc  |z Connect to this object online.